Metaclipse Therapeutics Corporation aims to be a leader in developing next-generation immunotherapies to treat cancer & vaccines to prevent infectious diseases using our proprietary biological adjuvants. Our personalized immunotherapy platform, Membrex™, has demonstrated promising preclinical data across multiple solid tumors with Phase 1 clinical trials for triple negative breast cancer (TNBC) and head and neck cancer (HNSCC) to begin in late 2023/early 2024. We are committed to continuous innovation using biological adjuvants for therapeutic and preventative vaccines.
Membrex™ and VaxRex™ are investigational therapies and have not been approved for any indication by the Food and Drug Administration (FDA) or any other regulatory agency. The safety and efficacy of these therapies have not been determined.